Veraxa Biotech (VRXA) vs Whitehawk Therapeutics (WHWK)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Whitehawk Therapeutics (WHWK) has outperformed Veraxa Biotech (VRXA) over the past year, gaining 62.2% versus a loss of 88.0%. Whitehawk Therapeutics is the larger company by market cap ($200.7 million vs $178.2 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | VRXA | WHWK |
|---|---|---|
| Share price | $1.26 | $3.52 |
| Market cap | $178.17M | $200.67M |
| 1-day change | +15.60% | +1.44% |
| YTD return | -88.19% | +45.45% |
| 1-year return | -87.97% | +62.21% |
| 5-year return | — | -87.06% |
| EPS (TTM) | $-0.57 | $-1.14 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $27.36 | $5.50 |
| 52-week low | $1.04 | $1.87 |
| Distance from 52-week high | -95.39% | -35.94% |
| Analyst consensus | — | buy |
| Avg. price target upside | — | +119.03% |
| Average volume | 267.20K | 367.72K |
| Shares outstanding | 141.41M | 57.01M |
| Employees | — | 32 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- WHWK has outperformed VRXA by 150.2 percentage points over the past year.
About Veraxa Biotech
VRXA stock →VERAXA Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation.
Health Care · Biotechnology: Pharmaceutical Preparations
About Whitehawk Therapeutics
WHWK stock →Whitehawk Therapeutics, Inc., a clinical-stage oncology therapeutics company that develops technologies to establish tumor biology for cancer treatments. It provides three next generation antibody drug conjugates (ADC) portfolio to treat cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 32 employees
VRXA vs WHWK FAQ
Which is bigger, Veraxa Biotech or Whitehawk Therapeutics?
Whitehawk Therapeutics (WHWK) is larger, with a market capitalization of $200.67M compared with $178.17M for Veraxa Biotech (VRXA).
Which stock has performed better over the past year, VRXA or WHWK?
WHWK returned +62.21% over the past 12 months, compared with -87.97% for VRXA (price return, excluding dividends). Past performance does not predict future results.
Are Veraxa Biotech and Whitehawk Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.